Abstract. It has long been thought that functional regeneration of the injured central nervous system (CNS) is impossible, as Santiago Ram6ny Cajal described in the early 20th century, "once the devel opment was ended, the fonts of growth and regeneration...dried up irrevocably". In mammalian neural development, most neuronal production (neurogenesis) occurs in the embryonic stage. How ever, recent findings indicate that neurogenesis continues in the olfactory bulb, hippocampus, and dentate gyrus of adult mammalian animals, from the neural stem cells (NSCs). Recently developed techniques have made it possible to isolate, culture, and grow pluripotent self-renewing NSCs from both embryonic and adult brains. This basic research is attracting a lot of attention because of the hope that it will lead to regeneration and reconstruction therapy for the damaged CNS. In this review, recent fi ndings on the stem cell biology of the CNS and strategies for its potential therapeutic application will be discussed. 
Neural stem cells (NSCs) are defined as undiffer entiated cells that are able to self-renew as well as gen erate the three major cell types that constitute the cen tral nervous system (CNS): neurons, astrocytes, and oligodendrocytes (pluripotency) (Fig. 1) . Notably, the presence of NSCs or neural stem-like cells is not a re cent concept, and a model close to the present one had already been proposed at the end of the 19th century: "there are neural precursor cells in the ventricular zone of the neural tube, which is the primordium of the CNS at the developmental stage (embryonic stage), and these precursor cells differentiate to neurons and glia".1 These neural precursors located at the ventricular zone of the fetal neural tube were observed in more detail in the 1960's and named "matrix cells".2 Building on the great achievements of our predecessors 100 years ago, continued research and modern technology have resulted in important advances, including the develop ment of both i) a selective culture method for NSCs and ii) an in situ identification method for NSCs using se lective markers. Making full use of these two develop ments, studies with great impact have recently been made, which report the discovery of NSCs at unex pected stages and places (for example, in the adult brain) and surprising properties of NSCs. In this review, the basic biological properties of NSCs and the rela tionship of adult neurogenesis with higher brain func tion and psychiatric diseases are discussed. Although related topics, such as the regulation of NSCs' self renewal and differentiation, the regional specificity of NSCs, and the acquisition of specific cell fates are very important, these issues are not described here, but they are discussed in other reviews. 3, 4 What Is an NSC?
Biologists studying stem cells of the hematopoietic system, small intestine, and skin described the basic properties of stem cells (somatic stem cells, not toti potential embryonic stem cells). These cells are: (a) undifferentiated, in which no specific differentiation marker is expressed, (b) able to proliferate, (c) able to self-maintain their population, (d) able to differentiate and generate many descendant cells with various func tions, and (e) able to repair injured tissue.5 However, it remains to be resolved whether stem cells in the ner- vous system strictly meet all these criteria; thus, the definition of NSCs differs slightly among individual researchers. In this review, I will consider the general characters of NSCs and progenitor cells to be as fol lows. The cell lineages generated from NSCs, which generate neurons, astrocytes, and oligodendrocytes dif fer among stages and regions of the CNS. In the cere bral cortex, NSCs generate intermediate progenitor cells that then generate specific cells6: neuronal pro genitor cells generate only neurons and glial progenitor cells generate only glial cells, as shown in Fig. 1 . In this cell fate process, pluripotential NSCs are committed to progenitor cells of a specific lineage. NSCs, neuronal progenitor cells, and glial progenitor cells are able to proliferate and are generally located in the periven tricular area. When these three types of cells are not distinguishable, they are collectively called, "neural progenitor cells".
NSCs can be clonogenically expanded in free fl oating "neurosphere" cultures. Researchers have used this system to define the NSCs experimentally and to quantify their multi-lineage potency and ability to self renew (Fig. 2) .7 However, an NSC cannot be identified prospectively as a neurosphere-initiating cell. That is, when the culture is started, we cannot tell which cell will form a neurosphere. Only after the neurosphere is formed can we conclude that the initial cell was an NSC, i.e., it is a retrospective identification.
Prospective Identification and Isolation of NSCs
Although there are highly selective marker mole cules for NSCs, such as Musashil (an RNA-binding protein) 8-13 nestin (an intermediate filament)
14,15 and members of Sox-family (transcription factors)," these markers, unlike those for hematopoietic stem cells, are not cell surface antigens and therefore could not be used to identify viable NSCs prospectively using fluorescence-activated cell sorting (FACS), until recently.3,17 To enable the prospective identification of viable NSCs, we first prepared a transgenic mouse (nestin-EGFP mouse) in which a fluorescent mole cule, enhanced green fluorescent protein (EGFP) , is expressed under the control of the 2nd intronic enhancer of the nestin gene, which acts highly selec tively for NSCs. We then isolated populations of EGFP expressing cells from the brains of these mice according to the expression level (i.e., fluorescence intensity) us ing FACS.18-20 The isolated cells were then inves tigated for the properties of NSCs, using mitotic activity (BrdU uptake), the efficiency of neurosphere forma tion, and self-renewal and pluripotency in low-density culture as indices. The GFP fluorescence intensity was correlated with these NSC-like biologic activities (Fig .  3) . 18 Because this method concentrates NSCs using FACS, without involving in vitro growth-factor-induced expansion (e.g., neurosphere culture) , it can be used for Fig. 2 Neurosphere formation assay. The major breakthrough for research on stem cell biology of the CNS was the development of the clo nogenic expansion of NSCs in floating culture, called "neurosphere culture," within a serum-free defined medium containing EGF and/or FGF2.7 A neurosphere derived from a single cell is capable of generating the major 3 lineages of the CNS, i.e., neurons, astrocytes, and oligo dendrocytes, indicating the multipotency of the neurosphere-initiating cell, upon the differentiation assay. If the neurosphere is dissociated into single cells, each cell starts to form a secondary neurosphere again with high frequency. NSCs by asymmetric divi sions .29-32 However, it is not clear whether the first neural cells that appear during ontogeny upon "neural induction" emerge from the initial FGF-2-responsive NSCs (reviewed by van der Kooy and Weiss33).
After neurulation
It has been long believed that NSCs are located in the ventricular zone of the neural tube after neurula tion.2 This is very consistent with the results of immu nohistochemical analysis using Musashil (Fig. 5 ). In the fetal neural tube, NSCs divide both symmetrically and asymmetrically.34 In the former, one cell divides into two identical daughter cells. This division occurs at the stage when the number of cells constituting the neural tube rapidly expands (one neuroepithelial cell produces two neuroepithelial cells: proliferative symmetric divi sion), before the generation of neurons begins. In asymmetric division, one cell divides into two different daughter cells. This division is necessary for generating the both differentiating cells and a stem cell by itself, and is a general characteristic of stem cells. In the mammalian CNS, NSCs (or neuronal progenitor cells that are able to generate only neurons) divide asym metrically in the ventricular zone of the neural tube , and neural stem (or neuronal progenitor) cells them selves and neurons are generated simultaneously . After neuronal generation begins, neural stem (or neuronal progenitor) cells continue to divide asymmetrically and generate different types of neurons, depending on what micro-environmental and cell-autonomous factors are present.35,36 The proliferative symmetric division of neuroepithelial cells is frequently observed at the rela tively early stage of neural tube genesis in the forebrain region in mammalian development. In this type of cell division, the cleavage plane is vertical to the ventricular wall, whereas in asymmetrical division the cleavage plane is horizontal to the ventricular wall; however, the underlying control mechanism is still unknown. In the embryonic tube, a portion of the NSCs (which can be called "fetal NSCs"), have a characteristic radial morphology and are generally known as radial glia (reviewed by Barres).37-40 Radial glia have long been thought to be involved in guiding or providing a scaf fold for the migration of newly generated neurons.41 Fetal NSCs are likely to play crucial roles in the histo genesis of the brain, in addition to the production of new neurons and glia (reviewed by Okano4).
Adult CNS
The generation of neurons does not just occur at the embryonic stage. It continues in adult rodents in two regions: the hippocampal dentate gyrus and olfactory bulb42.43 (reviewed by Temple and Alvarez-Buylla, Gage, Alvarez-Buylla and Garcia-Verdugo44-46). The localization of NSCs at the neurogenic sites in adult brain has been shown by the selection culture method for NSCs, the neurosphere method, and in situ identifi cation of NSCs using selective markers (Musashil, nes tin). It has been shown that interneurons in the olfac tory bulb are generated from NSCs that are localized to the periventricular area facing the lateral ventricle and that neuronal cells move all the way to the olfac tory bulb through a pathway called the rostral migra tory stream42.47.48 (reviewed by Temple and Alvarez- Buylla45). Furthermore, recent results indicate that, contrary to the current view, multipotential (neuronal astroglial-oligodendroglial) precursors with stem cell features can be isolated not only from the SVZ but also from the entire rostral extension, including the distal portion within the olfactory bulb.49 These find ings demonstrate that stem cells are not confined to the forebrain periventricular region and indicate that stem cells endowed with different functional characteristics occur at different levels of the SVZ-rostral extension (RE) pathway. Given the persistence of neurogenesis into adulthood, several attempts have been made to identify adult NSCs. Dr. van der Kooy and his col leagues reported the possible presence of stem cells in the SVZ facing the lateral ventricle in the adult brain, using various methods including the neurosphere method.50 Several years ago, we showed in a collabo rative study with Dr. Steven Goldman, that NSCs/ neuronal progenitor cells are present in adult human 48 On the other hand, Dr. Alvarez-Buylla and his colleagues recently used glial fibrillary acidic protein (GFAP), an astrocyte marker, and reported that GFAP-positive cells located in the SVZ are NSCs, at least in the pe riphery of the lateral ventricle.47 Using transgenic mice expressing a retrovirus receptor under the control of a GFAP promoter, they demonstrated that the GFAP positive cells in the SVZ gave rise to new neurons and, thus, concluded that SVZ astrocytes are NSCs.47 Whether ependymal cells or SVZ astrocytes are NSCs, it is of interest that a cell population previously consid ered to be glial cells includes NSCs and is related to neurogenesis in vivo. Anti-Musashil antibodies recog nize not only ependymal cells and SVZ neural progen itor cells but also some astrocytes in adults (Fig. 5) . 11 The subventricular layer/ependymal cell layer facing the lateral ventricle, where NSCs are localized, corre sponds to the neurogenic site in the adult brain. How ever, it is of more interest that NSCs are present even in non-neurogenic regions (reviewed by Temple and Alvarez-Buylla44). For example, NSCs were shown to exist in the ependymal layers surrounding the central canal of the adult spinal cord, where neurogenesis does not occur.48,52 However, the NSCs in this site expressed nestin-EGFP (Fig. 6 ), formed neurospheres, and generated new neurons in culture. Thus, neuro genesis from these NSCs is likely to be inhibited in vivo, particularly by local environmental factors. Even after spinal cord injury, neurogenesis is inhibited, although the NSCs are capable of producing astrocytes,48,52 which form glial scarring thereafter. Given these ex perimental findings, it is unlikely that the simple intro duction of NSCs into an injured region would improve the pathology, because the endogenous NSCs generate only glial cells and not neurons. Thus, in addition to the transplantation of NSCs, preparation of the microenvi ronment to induce neurogenesis would be essential. We recently demonstrated that delaying the transplantation of NSCs to 9 days after the spinal cord injury, when in hibitory cues that prevent neurogenesis are likely to be down-regulated,53 is important to achieve neurogenesis from the transplanted NSCs and functional recovery (Fig. 7) 
The presence of NSCs with both pluripotency and the ability to self-renew in adults has been shown by neurosphere culture.7,18,50 However, the sites of neu rogenesis in vivo are limited in adults. Analysis of the physiological significance of this finding is underway, focusing on NSCs involved in neurogenesis in vivo. It has been reported that experiencing of a 'desirable en vironment' increases adult neurogenesis (granule cells) by 15% in the hippocampaldentate gyrus in mice, and also increases the efficiency of space learning perfor mance (reviewed by Kemperman and Gage59). Recent studies have shown that newly generated neurons are physiologically active and are able to form new syn apses with older neurons.60 A fascinating thought, that "an additional 15% of neurons increased learning effi ciency" (reviewed by Kemperman and Gage59), may be proposed, but how new neurons form a neuronal network with existing neurons and whether the new neurons are really involved in learning have yet to be determined. Interestingly, it has been shown that inversely, a stressful experience markedly inhibits neu rogenesis. It is proposed that stress-induced decreases in neurogenesis within the hippocampal dentate gyrus are an important causal factor in precipitating episodes of depression. Reciprocally, it is speculated that thera peutic interventions for depression that increase sero tonergic neurotransmission act at least in part by aug menting dentate gyrus neurogenesis. 61 The reported results on adult neurogenesis in the neocortex have been controversial.62-64 claimed that neurogenesis occurs in the prefrontal area of the frontal lobe, the lower temporal association area, and the pos terior parietal association area in the cerebral neo cortical association area of adult macaque monkeys. These regions are associated with higher functions such as emotion, memory, and judgment. The detection of neurogenesis in this area attracted attention because it disproved previous beliefs and provided profound implications for understanding the cellular mechanisms of higher functions. However, Dr. Pasko Rakic and his colleagues' more recent results do not support the presence of neurogenesis in normal adult primate cor tex.64 In contrast to the results of Dr. Gould's group, Drs. Kornack and Rakic showed that, although numer ous BrdU-labeled cells were distributed throughout the cerebral wall, including the neocortex, these were identified as non-neuronal cells by careful immuno histochemical observations using confocal microscopy; evidence for newly generated neurons was limited to the hippocampus and olfactory bulb in adult macaque monkeys.64 Interestingly, however, this condition is likely to change upon injury. We found that significant neurogenesis was induced upon ischemia at least in some part of the neocortex in adult monkeys (Tonchev AB, Yamashima T, Zhao L, Okano HJ and Okano H: submitted).
Prospective for Cell Therapy of the Damaged CNS Regenerative medicine using stem cell biology is attracting a lot of attention. The adult mammalian CNS was traditionally considered to be lacking in regen eration ability, but it is now an important target of regenerative medicine. Strategies for regenerative therapy using a stem cell system are roughly divided into: i) the use of organ (or tissue) stem cells (e.g., NSCs), ii) the use of embryonic stem (ES) cells, and iii) the use of dedifferentiation/transdifferentiation of dif ferentiated cells. Therapeutic strategies should be de termined based on a comprehensive consideration of the available information. Each of these strategies is reviewed below.
Use of tissue stem cells (NSCs)
The presence of characteristic stem cells (tissue stem cells) has been confirmed in many organs or tissues within a mature body. As discussed above, stem cells are self-renewing undifferentiated cells with pluripo tency, and the ability to contribute to tissue repair after injury may be added to the definition. The high poten tial for tissue stem cells to be applied to the regenera tive therapy for various organs can be predicted from these definitions. The first successful organ regenera tion using the tissue stem cell system was bone marrow transplantation.65 In addition to the hematopoietic sys tem, there is evidence for stem cells in many organs, such as the liver, intestinal tract, skeletal muscle, mam mary gland, neural crest (peripheral nervous system and smooth muscle), skin, and CNS. Indeed, NSCs are tissue stem cells of the CNS. As described above, several groups, including ours, have sought to estab lish a technique for the prospective identification of NSCs. 17 54 Further study using a primate donor and recipient will yield useful informa tion for the application of these findings to humans. The range of NSC applications aimed at regeneration of the CNS is not limited to cell therapy by transplantation. The investigation of how endogenous NSCs are acti vated and induced to contribute to organ self-repair are also important areas of research.
Use of embryonic stem cells (ES cells)
ES cells are undifferentiated stem cell lines estab lished from the epiblasts that are present in the inner cell mass (ICM) of an early embryo at the blastocyst stage. Epiblasts differentiate into three germ layers that will later form the body in the developmental process and thus, they are stem cells that are able to differenti ate into the three germ layers. ES cells can be induced to differentiate to various cells derived from the three germ layers under various culture conditions, and hu man ES cell lines have been established; therefore, ES cells have been a focus of regenerative medicine." To date, various cell types, including those of the ner vous system, fat, smooth muscle, skeletal muscle, the hematopoietic/vascular system, and cardiac muscle have been derived from ES cells.
Several studies have applied ES cells to the ner vous system. When glial progenitor cells derived from mouse ES cells were injected into rat mutants showing hypomyelination,82 the tissue was stained with an anti body against a myelin-specific protein marker, PLP. Recently, Dr. Ole Isacson and his colleagues showed that transplanting low doses of undifferentiated mouse ES cells into the striatum of a rat PD model (6-OH DA unilaterally-lesioned hemiparkinsonism) results in a proliferation of ES cells into fully differentiated DA neurons and a gradual and sustained behavioral resto- ration.83 However, teratoma developed in rare in stances after transplantation in these cases, indicating that improvements to this procedure still need to be designed and tested before it can be applied as a cell therapy for PD. Dr. Yoshiki Sasai and his colleagues at Kyoto University reported that DA neurons are effi ciently induced in vitro when mouse or monkey ES cells are co-cultured with PA-6 cells (stromal cells), and that these neurons survive after their transplantation into the striata of PD model mice.84,85 This method makes it possible to derive DA neurons from ES cells, but the derived DA neurons are intermingled with other types of cells. To apply this method to therapy , it is necessary to purify the dopaminergic neurons and to exclude other types of cells, including undifferentiated ES cells , which could form a teratoma after transplantation . We developed a reporter gene (TH-EGFP) containing cDNA encoding green fluorescence protein under the control of the promoter for tyrosine hydroxylase , the key enzyme of dopamine biosynthesis86 and designed a system for purifying TH-positive neurons using the TH EGFP reporter gene and cell sorter (Fig . 8) . Neverthe-less, it is also important to investigate whether the introduced ES cell-derived dopaminergic neurons are functional in vivo. It was recently shown that, in many neurodegenerative diseases including PD, specific neu rons are selectively lost (amyotrophic lateral atrophy [ALS], motor neurons; Huntington's chorea, striatal GABAnergic neurons; and cerebellar ataxia, cerebellar neurons including Purkinje cells). This implies that treatment of such diseases using ES technology would require a two-step strategy: efficient derivation of these neurons from ES cells and their selective isolation. 87 As human ES cells become more available, the fol lowing points should be addressed regarding their us age in medical treatment: I) The direct transplantation of ES cells induces teratoma, as observed in immuno deficient animals such as SCID mice. It would be better to induce ES cell differentiation to a more mature state, i.e., more like the cells constituting the body, then transplant them, rather than to transplant them directly. II) Even when cells are induced to differentiate, various cell types are derived in the differentiation via the for mation of the embryoid body, and separation of the specific cells required for the therapy is necessary. III) The possibility of immunological rejection always exists in transplantation therapy, except with autografts. It is theoretically possible to perform therapeutic cloning, in which human ES cell pools of each HLA type are prepared or nuclear transferred ES cells are generated (ntES cells) by denucleating an unfertilized oocyte, injecting the somatic cell nucleus of a specific person into the embryo, culturing the embryo until the blasto cyst stage, and establishing ES cells of the specific per son from the inner cell mass of the cloned embryo. The preparation of a human embryonic clone reported by a US venture business group, Advanced Cell Technology Co. and was sparked widespread debate about the ethics of this research. 88 The human embryonic clone prepared by this group divided only to the 6-cell stage and embryogenesis did not reach the blastocyst stage, which is thought to be required for the establishment of ES cells. However, when they induced the partheno genesis of an unfertilized oocyte that had completed the second meiosis, using cytochalasin B treatment and a calcium ionophore, the embryogenesis progressed to the blastocyst stage. Notably, ES cells were recently established from non-human primate parthenogenic blastocysts (termed, "parthenogenic stem cells", PS cells).89 It is still unclear whether PS cells can be used as immune-rejection-free donor cells in regenerative therapy, because the consequences of the homozygosity of recessive mutations in these cells are unknown.
The implications of these recently developed ES cell technologies in therapeutic applications have only be gun to be discussed. It is critical to discuss the ethical issues associated with studies using human ES cells, which are complex, and attitudes vary among countries.
Use of dedifferentiation/transdifferentiation
Tissue stem cells have been found in various organs, and these stem cells supplement differentiated cells lost due to physiological turnover or injury. Accordingly, until a few years ago, it was commonly thought that endogenous tissue stem cells in each organ only gener ate cells that are specific to that organ. However, this view was challenged by one study in which the differ entiation and proliferation of hematopoietic cells were derived from NSCs. 90 Although there has been some difficulty reproducing this particular result,91 since this report, other studies on the reprogramming, or "plas ticity," including transdifferentiation and dedifferentia tion of mammalian cells have appeared in the literature. These recent studies include: I) the transdifferentiation of bone-marrow-derived cells into neural cells,92-91 II) the transdifferentiation between muscle and bone marrow-derived cells,96,97 III) the transdifferentiation of bone marrow cells98,99 or purified hematopoietic stem cells100 into liver cells; IV) the differentiation of purified NSCs injected into a blastocyst into various cells other than nervous system cells,101 V) the conver sion of NSCs to skeletal muscle upon co-culturing,102 VI) the dedifferentiation of oligodendrocyte progenitor cells into NSCs under certain culture conditions,103 VII) the differentiation of skin cells (dermis) into neu rons, glial cells, and fat cells,104 VIII) the differentia tion of cord blood cells into neural cells,105 and the multiorgan and multilineage potential of a single bone marrow-derived stem cell upon engraftment. 106 These findings indicate that the ability of stem cells to differentiate, which was thought to be tissue-specific, is unexpectedly flexible. It has been proposed that a few pluripotential cells like ES cells exist in each organ in a mature body and that such cells differentiate into spe cific cells under specific conditions.107 However, some studies reported in the last few years have been difficult to reproduce. Unfortunately, the study reporting that NSC-derived blood was obtained from a mouse that had received an intravenous injection of NSCs from another mouse has not been confirmed by an additional study. The latest thinking is that the phenomenon that was considered to be the plasticity of stem cells is more likely to result from the fusion of transplanted cells and host cells.108.109 Previous studies reporting the conver sion of transplanted bone marrow cells into unexpected cell types in vivo92, 93, 96, [98] [99] [100] 106 based the apparent transdifferentiation on the presence of a donor-derived marker (i.e., the Y chromosome when the donor is male and the recipient is female or the expression of a donor specific gene) in cells that had acquired a new pheno type within the recipient animals . However, a recent report by Terada et al.108 raises the alternative pos sibility that donor bone marrow cells can fuse with recipient somatic cells in vivo and that this process may contribute to some of the apparent "donor-typed" cells in various organs, although in this study, which characterized the phenomenon in vitro, the frequency of the spontaneous cell fusion was very low (2-11 clones per 106 bone marrow cells). Careful investiga tion of this issue using both donor and recipient derived markers will be necessary to clarify the mecha nisms involved.
Although it is difficult to distinguish from repro gramming or plasticity, unexpected pluripotency has been observed in mesenchymal stem cells (MSC) in bone marrow interstitium, and skin-derived precursors (SKP) in vitro,104 in which the phenotype is not likely to result from cell fusion. In addition to osteoblasts, MSCs have been shown to differentiate into hep atocytes, skeletal muscle, cardiac muscle, ccartilage, fat cells, and neural cells in culture.94,95,110-112 From SKP, neurons, astrocytes, oligodendrocytes, fat cells, and smooth muscle cells were differentiated.104 Although many issues remain to be resolved, such as whether differentiation can cross germ layers and the difficulty in distinguishing MSC's diversity from pluripotency, it is likely that we will see the day when MSCs can be recovered by bone marrow puncture at an outpatient clinic and applied in autografts for the treatment of various organ deficiencies.
Perspectives for the Future
Regenerative therapies that take advantage of stem cell technology for CNS damage including neurological diseases hold tremendous hope for the future. Although most studies aimed at the realization of these therapies are still at the basic stage, researchers worldwide, driven by the high competition in this field, may begin focusing more on clinical application. Obviously, it is important to approach this goal in a step-by-step man ner, following animal experiments using progressively modified technology with studies in small numbers of patients that apply well validated assessment protocols. Many achievements in basic science have been made in Western countries, mainly the United States, but the United States has not always occupied a leading posi tion, as it did in the genome project. Nonetheless, the United States is investing 100 million dollars in ES cell research and 200 million dollars in somatic stem cell research and development from the federal budget in the next financial year (2002), which will accelerate the research. In Japan, before medical applications of the three strategies described above can be realized, guidelines for stem-cell therapy, quality control systems to confirm the efficacy and safety of the procedures, 
